BRPI0617167B8 - sulfonilpirróis como inibidores de hdac's, seu uso, composição farmacêutica e combinação - Google Patents

sulfonilpirróis como inibidores de hdac's, seu uso, composição farmacêutica e combinação

Info

Publication number
BRPI0617167B8
BRPI0617167B8 BRPI0617167A BRPI0617167A BRPI0617167B8 BR PI0617167 B8 BRPI0617167 B8 BR PI0617167B8 BR PI0617167 A BRPI0617167 A BR PI0617167A BR PI0617167 A BRPI0617167 A BR PI0617167A BR PI0617167 B8 BRPI0617167 B8 BR PI0617167B8
Authority
BR
Brazil
Prior art keywords
sulfonylpyrroles
combination
pharmaceutical composition
hdac inhibitors
inhibitors
Prior art date
Application number
BRPI0617167A
Other languages
English (en)
Inventor
Volz Jurgen
Feth Martin
Muller Matthias
Hummel Rolf-Peter
Beckers Thomas
Bär Thomas
Maier Thomas
Original Assignee
Nycomed Gmbh
Takeda Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh, Takeda Gmbh filed Critical Nycomed Gmbh
Publication of BRPI0617167A2 publication Critical patent/BRPI0617167A2/pt
Publication of BRPI0617167B1 publication Critical patent/BRPI0617167B1/pt
Publication of BRPI0617167B8 publication Critical patent/BRPI0617167B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

SULFONILPIRRÓIS COMO INIBIDORES DE HDAC'S. A presente invenção refere-se a compostos de uma certa fórmula I, em que R1, R2, R3, R4, R5, R6 e R7 têm os significados indicados na descrição, bem como os sais dos mesmos são novos inibidores de HDAC eficazes.
BRPI0617167A 2005-09-21 2006-09-08 sulfonilpirróis como inibidores de hdac's, seu uso, composição farmacêutica e combinação BRPI0617167B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05108728 2005-09-21
EP05108728.6 2005-09-21
PCT/EP2006/066197 WO2007039404A1 (en) 2005-09-21 2006-09-08 Novel sulphonylpyrroles as inhibitors of hdac s novel sulphonylpyrroles

Publications (3)

Publication Number Publication Date
BRPI0617167A2 BRPI0617167A2 (pt) 2011-07-12
BRPI0617167B1 BRPI0617167B1 (pt) 2021-02-09
BRPI0617167B8 true BRPI0617167B8 (pt) 2021-05-25

Family

ID=37035343

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0617167A BRPI0617167B8 (pt) 2005-09-21 2006-09-08 sulfonilpirróis como inibidores de hdac's, seu uso, composição farmacêutica e combinação

Country Status (26)

Country Link
US (1) US8232297B2 (pt)
EP (1) EP1928872B1 (pt)
JP (1) JP5305910B2 (pt)
KR (1) KR101256846B1 (pt)
CN (1) CN101268070B (pt)
AR (1) AR057824A1 (pt)
AT (1) ATE549333T1 (pt)
AU (1) AU2006298882B2 (pt)
BR (1) BRPI0617167B8 (pt)
CA (1) CA2622673C (pt)
CY (1) CY1112780T1 (pt)
DK (1) DK1928872T3 (pt)
EA (1) EA016345B1 (pt)
ES (1) ES2381962T3 (pt)
HK (1) HK1124320A1 (pt)
HR (1) HRP20120399T1 (pt)
IL (1) IL189782A (pt)
NO (1) NO341744B1 (pt)
NZ (1) NZ566074A (pt)
PL (1) PL1928872T3 (pt)
PT (1) PT1928872E (pt)
RS (1) RS52383B (pt)
SI (1) SI1928872T1 (pt)
TW (1) TWI406846B (pt)
WO (1) WO2007039404A1 (pt)
ZA (1) ZA200801394B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000041698A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
PT1478358E (pt) 2002-02-11 2013-09-11 Bayer Healthcare Llc Tosilato de sorafenib para o tratamento de doenças caracterizadas por angiogénese anormal
PL1626714T3 (pl) 2003-05-20 2007-12-31 Bayer Healthcare Llc Diarylowe pochodne mocznika do schorzeń, w których pośredniczy PDGFR
CN1856469B (zh) 2003-07-23 2013-03-06 拜耳医药保健有限责任公司 用于治疗和预防疾病和疾病症状的氟代ω-羧芳基二苯基脲
AR048427A1 (es) 2004-03-11 2006-04-26 Altana Pharma Ag Derivados de sulfonilpirroles con actividad inhibitoria de la histona deacetilasa, composiciones farmaceuticas que los contienen y el uso de las mismas para el tratamiento de enfermedades relacionadas.
DK1861365T3 (da) 2005-03-15 2009-08-24 4Sc Ag N-sulfonylpyrroler og anvendelse deraf som histondeacetylaseinhibitorer
CA2622670A1 (en) * 2005-09-21 2007-04-12 Nycomed Gmbh Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors
ES2381962T3 (es) 2005-09-21 2012-06-04 4Sc Ag Nuevos sulfonilpirroles como inhibidores de las HDAC
EP2100882A1 (en) * 2008-03-12 2009-09-16 4Sc Ag (E) -N -(2-Amino-phenyl) -3-{1-[4-(1-methyl-1H-pyrazol-4-yl)- benzenesulfonyl]-1H-pyrrol-3-yl} -acrylamide salts
EP2100878A1 (en) * 2008-03-12 2009-09-16 4Sc Ag Novel method for the production of sulphonylpyrroles as HDAC inhibitors
CA2735593C (en) 2008-09-03 2017-08-15 Repligen Corporation Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
WO2012118782A1 (en) 2011-02-28 2012-09-07 Repligen Corporation Histone deacetylase inhibitors
KR102017070B1 (ko) * 2011-09-30 2019-09-02 다나-파버 캔서 인스티튜트 인크. 치료 펩티드
CN104136410A (zh) * 2011-12-29 2014-11-05 药品循环公司 作为组蛋白脱乙酰酶8抑制剂的肉桂酸羟基酰胺
US9464089B2 (en) 2012-01-13 2016-10-11 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
US10799504B2 (en) 2012-01-13 2020-10-13 ACEA Therapeutics, Inc. Heterocyclic compounds and uses as anticancer agents
JP6215938B2 (ja) * 2012-08-06 2017-10-18 エイシア バイオサイエンシーズ インコーポレイテッド プロテインキナーゼの阻害剤としての新規ピロロピリミジン化合物
AU2014228344C1 (en) 2013-03-15 2019-02-07 Biomarin Pharmaceutical Inc. HDAC inhibitors
CN105916851A (zh) 2013-07-11 2016-08-31 艾森生物科学公司 嘧啶衍生物作为激酶抑制剂
CN107949388B (zh) 2015-10-09 2021-10-26 艾森医药公司 吡咯并嘧啶激酶抑制剂的药用盐、物理形态和组合物及其制备方法
CN105622680B (zh) * 2015-12-22 2018-01-19 杭州卢普生物科技有限公司 一种舒尼替尼衍生物及其制备方法和应用
WO2017178577A1 (en) 2016-04-14 2017-10-19 4Sc Ag Medical application of resminostat in asian patients
CN111212837A (zh) 2017-04-07 2020-05-29 艾森医药公司 吡咯并嘧啶激酶抑制剂的药用盐、物理形态和组合物及其制备方法
TW201912183A (zh) 2017-08-31 2019-04-01 德商４Ｓｃ製藥公司 Hdac抑制劑與抗代謝藥劑組合用於癌症治療
CN110496136A (zh) * 2018-05-17 2019-11-26 王孝恩 锂制剂在制备治疗或预防癌症药物中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960787A (en) 1989-02-06 1990-10-02 Ciba-Geigy Corporation Certain pyrrolyl-substituted hydroxamic acid derivatives
ES2107557T3 (es) 1991-12-10 1997-12-01 Shionogi & Co Derivado de acido hidroxamico a base de sulfonamida aromatica.
WO1996038418A1 (en) 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
KR20020070285A (ko) 1999-11-23 2002-09-05 메틸진, 인크. 히스톤 디아세틸라제의 억제제
WO2001038323A1 (en) 1999-11-23 2001-05-31 Merck & Co., Inc. Pyrazinone thrombin inhibitors
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
HUP0401963A3 (en) 2001-08-09 2006-01-30 Ono Pharmaceutical Co Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
JP3795044B2 (ja) 2001-09-14 2006-07-12 メシルジーン、インコーポレイテッド ヒストンデアセチラーゼの阻害剤
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
AU2003298567B9 (en) 2002-08-29 2009-07-23 Temple University - Of The Commonwealth System Of Higher Education Aryl and heteroaryl propene amides, derivatives thereof and therapeutic uses thereof
GB0226855D0 (en) 2002-11-18 2002-12-24 Queen Mary & Westfield College Histone deacetylase inhibitors
AU2004268621C1 (en) 2003-08-29 2011-08-18 Exelixis, Inc. c-Kit modulators and methods of use
CA2553513A1 (en) 2004-01-22 2005-08-04 Altana Pharma Ag N-4-(6- (heteo) aryl-pyrimidin-4-ylaminophenyl) -bezenesulfonamides as kinase inhibitors
US20050197336A1 (en) 2004-03-08 2005-09-08 Miikana Therapeutics Corporation Inhibitors of histone deacetylase
AR048427A1 (es) 2004-03-11 2006-04-26 Altana Pharma Ag Derivados de sulfonilpirroles con actividad inhibitoria de la histona deacetilasa, composiciones farmaceuticas que los contienen y el uso de las mismas para el tratamiento de enfermedades relacionadas.
US7345043B2 (en) 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
US7432808B2 (en) 2004-12-15 2008-10-07 Intel Corporation Wireless module enabled component carrier for parts inventory and tracking
DK1861365T3 (da) 2005-03-15 2009-08-24 4Sc Ag N-sulfonylpyrroler og anvendelse deraf som histondeacetylaseinhibitorer
AU2006232773B2 (en) 2005-04-07 2012-04-12 4Sc Ag Sulfonylpyrroles as histone deacetylase inhibitors
ES2381962T3 (es) 2005-09-21 2012-06-04 4Sc Ag Nuevos sulfonilpirroles como inhibidores de las HDAC
CA2622670A1 (en) * 2005-09-21 2007-04-12 Nycomed Gmbh Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors

Also Published As

Publication number Publication date
EA016345B1 (ru) 2012-04-30
RS52383B (en) 2012-12-31
BRPI0617167B1 (pt) 2021-02-09
CA2622673A1 (en) 2007-04-12
TW200745028A (en) 2007-12-16
ES2381962T3 (es) 2012-06-04
WO2007039404A1 (en) 2007-04-12
NO20081797L (no) 2008-04-17
CY1112780T1 (el) 2016-02-10
IL189782A (en) 2013-06-27
CA2622673C (en) 2017-06-27
CN101268070B (zh) 2012-09-05
EP1928872A1 (en) 2008-06-11
AU2006298882B2 (en) 2011-10-27
US20090263353A1 (en) 2009-10-22
JP2009508826A (ja) 2009-03-05
IL189782A0 (en) 2008-08-07
EP1928872B1 (en) 2012-03-14
TWI406846B (zh) 2013-09-01
HRP20120399T1 (hr) 2012-06-30
EA200800700A1 (ru) 2009-04-28
SI1928872T1 (sl) 2012-06-29
US8232297B2 (en) 2012-07-31
AU2006298882A1 (en) 2007-04-12
JP5305910B2 (ja) 2013-10-02
KR101256846B1 (ko) 2013-04-24
PL1928872T3 (pl) 2012-08-31
PT1928872E (pt) 2012-05-25
CN101268070A (zh) 2008-09-17
HK1124320A1 (en) 2009-07-10
ZA200801394B (en) 2009-12-30
BRPI0617167A2 (pt) 2011-07-12
AR057824A1 (es) 2007-12-19
NZ566074A (en) 2011-08-26
DK1928872T3 (da) 2012-05-07
NO341744B1 (no) 2018-01-15
ATE549333T1 (de) 2012-03-15
KR20080047607A (ko) 2008-05-29

Similar Documents

Publication Publication Date Title
BRPI0617167B8 (pt) sulfonilpirróis como inibidores de hdac's, seu uso, composição farmacêutica e combinação
ECSP20027480A (es) Indolil alquil amino derivados sustituidos como nuevos inhibidores de la histona desacetilasa
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
BRPI0819328A8 (pt) Compostos inibidores de replicação de vírus da imunodeficiência humana, composição farmacêutica e uso dos ditos compostos
GT200600134A (es) Compuestos novedosos de derivados de aminosulfonilo
BRPI0608148A2 (pt) [3.1.01] heteroaril amidas bicìclicas como inibidores de transporte de glicina do tipo i,composição farmacêutica para tratamento de distúrbio e seu uso
BR112015018751A2 (pt) derivados de piridazinona macrocíclicos
BRPI0513891B8 (pt) derivados de propenil piperazina substituídos, seu uso como novos inibidores de histona deacetilase, composição farmacêutica, combinação e processo de preparação destes
BRPI0608604B8 (pt) moduladores de 2,3-dioxigenase de indolamina e composição farmacêutica
BRPI0508464B8 (pt) sulfonilpirróis, composição farmacêutica compreendendo os mesmos e uso dos mesmos
BRPI0813244B8 (pt) compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário
UY30481A1 (es) Isoxazolinas sustituidas, composiciones farmaccuticas que contienen a las mismas, metodos de preparacion y usos.
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
BRPI0911035A2 (pt) ativadores de pirrolidinona glicoquinase
EA200870217A1 (ru) 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
BRPI1013821A8 (pt) piridinas substituídas como antagonistas de ccr3.
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
EA201100689A1 (ru) N-сульфонилпирролы и их применение в качестве ингибиторов гистондезацетилазы
BR112012024199A2 (pt) derivados de n-(imidazopirimidin-7-il)-heteroarilamida e seu uso como inibidores de pde10a
BR0309556A (pt) Inibidores de metaloproteinase pirimidina-2,4,6-triona
BRPI0717035B8 (pt) moduladores de benzotriazol cinase
ATE554085T1 (de) Neue inhibitoren von glutaminylcyclase
BRPI0915064B8 (pt) derivados de quinoxalinadiona, seus usos, e medicamentos
BRPI0817223B8 (pt) inibidores da interação entre mdm2 e p53, seu processo de preparação e seu uso, composição farmacêutica que os compreende e combinação
BRPI0507903A (pt) derivados de quinazolina e composição farmacêutica compreendendo os mesmos

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: TAKEDA GMBH (DE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/02/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/09/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: 4SC AG (DE)

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2614 DE 09/02/2021 QUANTO AO QUADRO REIVINDICATORIO.